Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTIrreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksTjeerd Barf* and Allard KapteinView Author Information Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands*Phone: +31 618 193139. E-mail, [email protected]Cite this: J. Med. Chem. 2012, 55, 14, 6243–6262Publication Date (Web):May 23, 2012Publication History Received7 March 2012Published online8 June 2012Published inissue 26 July 2012https://pubs.acs.org/doi/10.1021/jm3003203https://doi.org/10.1021/jm3003203review-articleACS PublicationsCopyright © 2012 American Chemical SocietyRequest reuse permissionsArticle Views13870Altmetric-Citations266LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Inhibition,Inhibitors,Kinase inhibitors,Monomers,Peptides and proteins Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [45]
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Research works printed but not linked: 5
- Powis G., 1994, Cancer Res., 54, 2419
- Wood E. R., 2008, Proc. Natl. Acad. Sci. U.S.A., 105, 2772
- Brigdes A. J., 2000, Chem. Rev., 101, 2541
- Advani, R.; Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study. Presented at the 11th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 15–18, 2011.
- Petter, R.Targeted Covalent Kinase Inhibitors: AVL 292 as a Potent, Irreversible and Selective Inhibitor of Btk. Presented at the 5th Anglo-Swedish Medicinal Chemistry Symposium (ASMC), Åre, Sweden, March 20–23, 2011.
Cited by
Items 201–300 of 386
Sun, M., Zhao, J., Chen, X., Zong, Z., Han, J., Du, Y., Sun, H., & Wang, F. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.007 · Cited by 18
Hu, J., Han, Y., Wang, J., Liu, Y., Zhao, Y., Liu, Y., & Gong, P. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.029 · Cited by 17
Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design
Yan, G., Zhong, X.-X., Pu, C., Lin, Y., Shan, H., Lan, S., Zhou, M., Hou, X., Yang, J., Li, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01707 · Cited by 14
Fan, D., Zhang, H., Duan, L., Li, L., Xu, S., Tu, Y., Wang, L., Zheng, P., & Zhu, W. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107390 · Cited by 14
New aminopyrimidine derivatives as inhibitors of the TAM family
Traoré, T., Cavagnino, A., Saettel, N., Radvanyi, F., Piguel, S., Bernard‐Pierrot, I., Stoven, V., & Legraverend, M. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.037 · Cited by 15
Yu, C.-H., Chou, C., Tu, H.-F., Huang, W.-C., Ho, Y.-Y., Khoo, K., Lee, M., & Chang, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25177 · Cited by 16
Shao, J., Liu, S., Liu, X., Pan, Y., & Chen, W. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115680 · Cited by 15
Seixas, J. D., Sousa, B. B., Marques, M. C., Guerreiro, A., Traquete, R., Rodrigues, T., Albuquerque, I. S., Sousa, M. F. Q., Lemos, A. R., Sousa, P. M. F., et al. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00033g · Cited by 16
Lifang, X., Yu, S., Liu, H., Yi, B., Wang, G., & Liu, Y. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03338-7 · Cited by 13
Kinetics, Thermodynamics, and Ligand Efficiency Metrics in Drug Discovery
Holdgate, G. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12318-2 · Cited by 23
Edlund, H., Buil‐Bruna, N., Vishwanathan, K., Wei, H., Raman, R. K., de Kock, M., He, Z., Liu, H., Baek, M. S., Ware, J. A., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15087 · Cited by 15
Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation
Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00010-7 · Cited by 17
Naven, R. T., Kantesaria, S., Nadanaciva, S., Schroeter, T., & Leach, K. L. (2013) · Toxicology Research · doi:10.1039/c3tx50027f · Cited by 14
High-throughput kinetics in drug discovery
Pinto, M. F., Sirina, J., Holliday, N. D., & McWhirter, C. L. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.100170 · Cited by 16
Kang, J.-B., Chen, L., Leng, X., Wang, J., Yang, C., Wu, S.-H., Ma, Y.-Y., Yang, L.-J., Cao, Y., Yang, X. C., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116937 · Cited by 14
Lee, E., Cho, H., Lee, D. K., Ha, J., Choi, B. J., Jeong, J. H., Ryu, J., Kang, J. S., & Jeon, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218006 · Cited by 13
Prejanò, M., Romeo, I., Serra, M. A. L., Russo, N., & Marino, T. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01012 · Cited by 13
A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors
Chen, Y.-C., & Zhang, C. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.106 · Cited by 12
Huang, Z., Zhang, Q., Yan, L., Zhong, G., Zhang, L., Tan, X., & Wang, Y. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.011 · Cited by 12
Small molecule inhibitors of anthrax edema factor
Jiao, G., Kim, S., Moayeri, M., Thai, A., Cregar, L., McKasson, L., O'Malley, S. W., Leppla, S. H., & Johnson, A. T. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.040 · Cited by 12
Miura, C., Shindo, N., Okamoto, K., Kuwata, K., & Ojida, A. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00547 · Cited by 12
Tichenor, M. S., Wiener, J. J. M., Rao, N. L., Deckhut, C. P., Barbay, J. K., Kreutter, K. D., Bacani, G. M., Wei, J., Chang, L., Murrey, H. E., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00044 · Cited by 12
Barragan, A. M., Ghaby, K., Pond, M. P., & Roux, B. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00023 · Cited by 11
Takenaka, K., Kaneko, K., Takahashi, N., Nishimura, S., & Kakeya, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116059 · Cited by 11
Identification of novel MEK1 inhibitors by pharmacophore and docking based virtual screening
Zou, F., Yang, Y., Ma, T., Xi, J., Zhou, J., & Zha, X. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-1788-y · Cited by 11
Dai, W., Samanta, S., Xue, D., Petrunak, E. M., Stuckey, J. A., Han, Y., Sun, D., Wu, Y., & Neamati, N. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01960 · Cited by 24
Exploring Extended Warheads toward Developing Cysteine-Targeted Covalent Kinase Inhibitors
Zhao, Z., & Bourne, P. E. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00890 · Cited by 12
On‐Membrane Supramolecular Assemblies Serving as Bioorthogonal Gating for Melphalan
Xu, H., Yao, Q., Hu, X., Zheng, D., Ren, C., Ren, Z., & Gao, Y. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202502922 · Cited by 10
Design, synthesis, and cytotoxic evaluation of novel scopoletin derivatives
Shi, W., Zhang, J., Bao, N., Guan, F., Chen, L., & Sun, J. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13120 · Cited by 10
Kharkar, P. S. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200502005853 · Cited by 11
Huang, F., Hu, H., Wang, K., Peng, C., Xu, W., Zhang, Y., Gao, J., Liu, Y., Zhou, H., Huang, R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00372 · Cited by 11
Covalent drug – An emerging framework for targeted drug development
Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V., & Chaudhari, S. Y. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101615 · Cited by 13
Discovery of quinoline-based irreversible BTK inhibitors
de Bruin, G., Demont, D., de Zwart, E., Verkaik, S., Hoogenboom, N., van de Kar, B., van Lith, B., Hoek, M. E.-V., Gulrajani, M., Covey, T. M., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127261 · Cited by 9
Self-citationCovalent fragment libraries in drug discovery—Design, synthesis, and screening methods
Hocking, B. J. W., Armstrong, A., & Mann, D. J. (2023) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2023.10.003 · Cited by 13
Focusing on probe-modified peptides: a quick and effective method for target identification
Sun, H., Ren, Y., Hou, W., Li, L., Zeng, F., Li, S., Ma, Y., Liu, X., Chen, S., & Zhang, Z. (2016) · Chemical Communications · doi:10.1039/c6cc04030f · Cited by 9
Total Synthesis and Antimicrobial Activity of Tumescenamide C and Its Derivatives
Takahashi, N., Kaneko, K., & Kakeya, H. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b03516 · Cited by 9
Naz, H., Tarique, M., Suhail, M., Shankar, H., Muhammad, N., Usmani, D., Ashraf, M., & Zughaibi, T. A. (2020) · Current Molecular Biology Reports · doi:10.1007/s40610-020-00138-9 · Cited by 9
Lin, X., Smaill, J. B., Squire, C. J., & Yosaatmadja, Y. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6nvi/pdb · Cited by 9
Developing Polo-like Kinase 1 Inhibitors
Huang, X., Xie, Z., & Liao, C. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0055 · Cited by 9
Research progress on covalent inhibitors targeting alkaline amino acids
Zhao, B., Xu, S., Zhou, S., Jiang, X., Jiang, A., Lei, H., & Zhai, X. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108800 · Cited by 9
Small-molecule FGFR-targeted medicinal chemistry: Advances since 2020 and future perspectives
Yue, H., Wang, Y., Zhang, N., Xing, J., Wang, T., Bao, Y., Hou, Y., & Zhao, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118117 · Cited by 9
Tumorspezifische, Hypoxie‐basierte Aktivierung von EGFR‐Inhibitoren
Karnthaler‐Benbakka, C., Groza, D., Kryeziu, K., Pichler, V., Roller, A., Berger, W., Heffeter, P., & Kowol, C. R. (2014) · Angewandte Chemie · doi:10.1002/ange.201403936 · Cited by 8
Jiang, M., Huizenga, M. C. W., Mohr, F., Amedi, A., Bakker, R., van den Berg, R. J. B. H. N., Deng, H., van der Wel, T., van Boeckel, C. A. A., & van der Stelt, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01037 · Cited by 9
An NMR-Guided Screening Method for Selective Fragment Docking and Synthesis of a Warhead Inhibitor
Khattri, R. B., Morris, D. L., Davis, C., Bilinovich, S. M., Caras, A., Panzner, M. J., DeBord, M. A., & Leeper, T. C. (2016) · Molecules · doi:10.3390/molecules21070846 · Cited by 9
Rossi, R., & Ciofalo, M. (2019) · Current Organic Chemistry · doi:10.2174/1385272823666191014154129 · Cited by 9
Coover, R. A., Luzi, N. M., Korwar, S., Casile, M. E., Lyons, C. E., Peterson, D. L., & Ellis, K. C. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00529b · Cited by 8
Covalent targeting of non-cysteine residues in PI4KIIIβ
Cosgrove, B., Grant, E. K., Bertrand, S. M., Down, K. D., Somers, D. O., Evans, J. P., Tomkinson, N. C. O., & Barker, M. D. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00142c · Cited by 8
Davies, A. J., Barrans, S., Burton, C., Mercer, K., Caddy, J., Chinnery, F. E., Day, L., Fernando, D., Ardeshna, K. M., Collins, G. P., et al. (2020) · F1000Research · doi:10.12688/f1000research.22318.1 · Cited by 7
Small Molecule Inhibitors of the Epidermal Growth Factor Receptor
Finlay, M. R. V., & Ward, R. A. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_26 · Cited by 10
Jia, Z., Xing, J., Li, J., Wang, W., Wang, Y., Song, Y., Yang, X., Xue, J., Ye, J., Li, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-107 · Cited by 8
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint
Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n-v2 · Cited by 9
Yao, H., Zhang, J., Zheng, Q., Zeng, X., Huang, H., Ling, Z., Tang, M., Chen, Z., Wang, W., & He, L. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202300753 · Cited by 7
A REVIEW ON PROTEIN TYROSINE PHOSPHATASES - AN IMPORTANT TARGET FOR VARIOUS DISEASES
Venkataraghavan, R., Devi, P. B., & Romauld, S. I. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i7.25615 · Cited by 6
A CDR-based approach to generate covalent inhibitory antibody for human rhinovirus protease
Cheng, Y., Wu, J., Han, Y., Xu, J., Da, Y., Zhao, Q., Guo, G., Zhou, Y., Chen, Y., Liu, J., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116219 · Cited by 6
Dou, D., Sha, W., Diao, Y., Su, R., Qiao, Y., Yu, Z., Zhao, Z., Li, H., Chen, Z., & Xu, Y. F. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105541 · Cited by 6
Qu, D., Yan, A., & Zhang, J. S. (2017) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2017.1284898 · Cited by 6
Zhang, Q., Hu, Z.-L., Shen, Q., Chen, Y., & Lu, W. P. (2017) · Molecules · doi:10.3390/molecules22050788 · Cited by 6
Das, D., Xie, L., & Hong, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109617 · Cited by 5
Lee, S. B., Yu, J., Kim, H., Kim, K. W., Jeong, J. W., Kim, Y. L., Park, S. J., Koo, T., Lee, C., Hong, K. B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01926 · Cited by 5
Occhipinti, M. A., Imbimbo, M., Ferrara, R., Simeon, V., Fiscon, G., Marchal, C., Skoetz, N., & Viscardi, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015140.pub2 · Cited by 15
Khattri, R. B., Morris, D. L., Bilinovich, S. M., Manandhar, E., Napper, K. R., Sweet, J. W., Modarelli, D. A., & Leeper, T. C. (2019) · Molecules · doi:10.3390/molecules25010147 · Cited by 5
Enhancing the Selectivity of Kinase Inhibitors in Oncology: A Chemical Biology Perspective
Maddox, S. M., Hecht, D., & Gustafson, J. L. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc.15.193 · Cited by 5
Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents
Aboul‐Soud, M. A. M., Al‐Sheikh, Y. A., Ghneim, H. K., Supuran, C. T., & Carta, F. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2355247 · Cited by 4
Discovery of Novel Irreversible HER2 Inhibitors for Breast Cancer Treatment
Tang, J.-Y., Ho, Y., Chang, C.-Y., & Liu, H. (2019) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2019.124016 · Cited by 5
The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success
Angiolini, M. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch16 · Cited by 5
Targeted Covalent Inhibitors for Novel Therapeutics
Zhang, J., Gao, W., Wang, Y., Chang, J., & Yu, B. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0243 · Cited by 4
Ai, Y., Yang, Z., Yang, Z., Wan, S., Huang, C., Huang, C., Li, M., Li, Z., Zhang, J., & Zhang, T. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00458 · Cited by 3
A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition
Sammons, R. M., & Dalby, K. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-48283-1_6 · Cited by 3
Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase
Zuo, Y., & Pan, Z. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_6 · Cited by 4
Enzyme Inhibition and Inactivation
Silverman, R. B., & Holladay, M. W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-382030-3.00005-2 · Cited by 6
Primik, M. F., Filak, L. K., & Arion, V. B. (2013) · doi:10.1002/9781118742952.ch45 · Cited by 3
Sabat, M. P., Dougan, D. R., Ermolieff, J., Halkowycz, P., Knight, B., Lawson, J. D., Scorah, N., Smith, C. R., Taylor, E. R., Vu, P. H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01685 · Cited by 3
Rebhan, L., Fürst, R., Schollmeyer, D., Serafim, R. A. M., & Gehringer, M. (2025) · ChemistryOpen · doi:10.1002/open.202500106 · Cited by 2
Ye, Q., & Ma, S. (2026) · Molecules · doi:10.3390/molecules31081272 · Cited by 2
Juanes‐Gusano, D., Fernández-Roldán, B., Coveñas, R., & Hijazi, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156590 · Cited by 3
Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00018-2 · Cited by 2
325 Identification and characterization of an irreversible inhibitor of CDK2
Martin, M., Anscombe, E., Meschini, E., Staunton, D., Geitmann, M., Danielson, U. H., Wang, L. Z., Vidal, R., Reuillon, T. D., Golding, B. T., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70451-4 · Cited by 2
In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors
Salowe, S. P., Zhang, L., Zokian, H. J., Gesell, J. J., Zink, D. L., Wiltsie, J., Ai, X., Kavana, M., & Pinto, S. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116657312 · Cited by 2
Kleemann, A. (2014) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.r22_r01 · Cited by 2
The Use of IC 50 for Potency and MTD as Objective in Study BIA 10–2474
van Iersel, M. T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.995 · Cited by 2
Molecular Dynamics-Guided Design and Chemoproteomic Profiling of Covalent Kinase Activity Probes
Chakraborty, P., Carlos, A. J., Thomas, T., Ghaby, K., Fathi, S., Sharma, M., Nguyen, N. K., Farmwald, M., Blachowicz, L., Alcyone, E., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c18691 · Cited by 2
Schwer, M., Aldea, S., Engelhardt, M., Stahlecker, J., Rheinganz, J., Langkamp, A., & Boeckler, F. M. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s598622 · Cited by 1
Developments in the design and therapeutic applications of GSK3β inhibitors
Daoud, S., & Taha, M. O. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2675873 · Cited by 1
Application of Quantitative Biomeasures in Early Drug Discovery
Fountain, S. T., & Vicini, P. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-40793-7_4 · Cited by 1
Lategahn, J., Keul, M., & Rauh, D. (2017) · Angewandte Chemie · doi:10.1002/ange.201710398 · Cited by 1
Alemi, H., Khavandgar, N., Oskouie, I. M., Mardani-Fard, H. A., Rostami, T., Aletaha, A., Peykari, N., Alikhani, M., Sajjadi‐Jazi, S. M., Kasaeian, A., et al. (2024) · Medicine · doi:10.1097/md.0000000000038511 · Cited by 2
Photo-crosslinking of clinically relevant kinases using H89-derived photo-affinity probes
Stolze, S. C., Liu, N., Wijdeven, R. H. M., Tuin, A. W., van den Nieuwendijk, A. M. C. H., Florea, B. I., van der Stelt, M., van der Marel, G. A., Neefjes, J., & Overkleeft, H. S. (2016) · Molecular BioSystems · doi:10.1039/c6mb00257a · Cited by 1
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
Lima, L. M., Barbosa, M. L. D. C., do Amaral, D. N., & Barreiro, E. J. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_95 · Cited by 2
Compound Attrition at the Preclinical Phase
Hop, C. E. C. A. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch2 · Cited by 3
A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint
Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Ralhan, K., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n · Cited by 4
Zhao, Z., & Bourne, P. E. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-b0bbz · Cited by 1
Selektives Tumor‐Targeting mit Prodrugs
Oltmanns, D. (2015) · Chemie in unserer Zeit · doi:10.1002/ciuz.201580016
Covalent Kinase Inhibitors for Cancer
Owens, T. D., & Lou, Y. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12399-6 · Cited by 1
Antineoplastic and Immunomodulating Agents (L)
Kleemann, A. (2017) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub3
Khattri, R. B. (2016) · OhioLink ETD Center (Ohio Library and Information Network) · doi:10.13140/rg.2.2.34723.58400
Using Biophysical Methods to Optimize Compound Residence Time
Holdgate, G. A., Rawlins, P. B., Biśta, M., & Stubbs, C. J. (2017) · Wiley eBooks · doi:10.1002/9781119099512.ch11 · Cited by 1
Modeling Covalent Protein-Ligand Interactions
Ward, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11519-3
In Vivo Targeting of Endogenous Proteins with Reactive Small Molecules
Shindo, N., & Ojida, A. (2019) · Wiley eBooks · doi:10.1002/9783527344406.ch10
Modulating the Reactivity of Electrophilic Warheads for Pharmacokinetic Efficacy
Bogatchenko, M. (2018) · TSpace (University of Toronto)
JAK Family Inhibitors for Autoimmune Diseases
Borzilleri, R. M., Hart, A. C., Moslin, R. M., Tokarski, J. S., & Wrobleski, S. T. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc279 · Cited by 1
Metadata
- Authors
- Barf, T., & Kaptein, A.
- Affiliations
- Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands
- Corresponding author
- Barf, Tjeerd
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-06-08
- Volume
- 55
- Issue
- 14
- Pages
- 6243-6262
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2057079741
- Cited by
- 331
- References
- 108
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 21 · 2023: 17 · 2022: 9 · 2021: 30 · 2020: 38 · 2019: 26 · 2018: 22 · 2017: 38 · 2016: 32 · 2015: 22 · 2014: 25 · 2013: 14 · 2012: 7
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- kinase inhibitors, covalent inhibitors, drug development, benefits and risks, kinase-targeted therapy
- MeSH terms
- Animals, Cell Line, Humans, Protein Kinases, Risk, Structure-Activity Relationship, Time Factors, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.